Bruno Vision Care has received U.S. Food and Drug Administration (FDA) approval for its Deseyne® (vifilcon C) daily disposable contact lenses, featuring a novel hydrogel material with patented controlled-release technology. The company claims these are the only lenses available globally that deliver hydration directly from the matrix of the lens itself.
The approval marks a significant advancement in contact lens technology, potentially addressing one of the most common complaints among wearers: dryness and discomfort.
Breakthrough Dual-Innovation Technology
Deseyne® lenses integrate two key patented innovations: the vifilcon C material, a unique enriched hydrogel, and the proprietary FusionTechnology™ delivery system. During manufacturing, bioactive substances called Lachryceuticals® – including amino acids, vitamins, and polysaccharides – are embedded within the lens matrix.
The patented controlled-release mechanism gradually delivers these substances to the anterior segment of the eye throughout the wearing period. This ensures continuous bioavailability of the hydrating compounds, providing what the company describes as "natural, long-lasting comfort."
"Deseyne® isn't just another contact lens, it defines a completely new category by incorporating a patented delivery system directly into the lens," said Eddie Catalfamo, CEO of Bruno Vision Care. "With our patented FusionTechnology™ proprietary manufacturing process and the novel vifilcon C material, we're setting a new standard in vision health."
How the Technology Works
The FusionTechnology™ combines hyaluronic acid (HA) with Tamarind Seed Polysaccharides (TSP®) to create a natural bio-copolymer that mimics natural tears. This substance is released steadily throughout the day, activated by physiological factors including body temperature, blinking, and eyelid pressure.
These Lachryceuticals® integrate with the eye's natural tear film, improving hydration, comfort, and stability – addressing key factors that often lead to contact lens intolerance.
Expert Perspective on Clinical Significance
Dr. Paul Karpecki, a recognized authority in dry eye disease with over 25 years of experience in the field, highlighted the unique aspects of the technology.
"There is nothing like the Deseyne® lens with FusionTechnology™ on the market today," Karpecki stated. "The unique design releases Lachryceuticals® – key components of the tear film – in a controlled, continuous manner throughout the day, maintaining eye hydration and comfort that no other lens can achieve."
Karpecki emphasized the potential impact on contact lens retention rates, noting that "dryness is the leading cause of performance issues in contact lens wearers and the primary reason over 18% of these patients drop out each year."
Market Impact and Availability
Bruno Vision Care expects to make Deseyne® lenses available to U.S. consumers in the fourth quarter of 2025. The company sees significant opportunity in the multi-billion-dollar global soft contact lens market, which Catalfamo described as having "seen little innovation in recent years."
"U.S. FDA approval is a major milestone for Bruno Vision Care as we set out to bring radical innovation to the multi-billion-dollar global soft contact lens market," Catalfamo said. "We see a significant opportunity to gain market share by delivering truly groundbreaking products that meet consumer needs."
The company believes several factors position them for success, including an aging population, rising disposable income, technological advancements, and increasing incidence of distance vision impairment.
Company Background
Bruno Vision Care LLC was established in 2019 as a subsidiary of Bruno Farmaceutici, which the company describes as Italy's third-largest pharmaceutical company with expertise in diabetes, pain management, and vision health.
The company brings "the experience of a proven management team and a seasoned medical advisory board" to launch Deseyne® lenses in the U.S. market, according to their announcement.
Catalfamo acknowledged the collaborative effort behind the FDA approval: "Bringing this breakthrough to the U.S. market has been our mission for many years, and we could not have achieved this without the hard work and determination of our U.S. and Italian teams."
